Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
2 hedge funds and large institutions have $25K invested in Lixte Biotechnology Warrants in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.88% less ownership
Funds ownership: 1.21% → 0.33% (-0.88%)
33% less funds holding
Funds holding: 3 → 2 (-1)
80% less capital invested
Capital invested by funds: $125K → $25K (-$100K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$107K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$335 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $20K | +$14.2K | +21,642 | +151% |
|
|
2
UBS Group
Zurich,
Switzerland
| $5K | -$335 | -510 | -6% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| – | -$107K | -140,089 | Closed |
|
LIXTW Hedge Fund Activity: Q3 2021 in Review
2 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q3 2021, worth a combined $25K — down 80% from $125K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LIXTW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Warberg Asset Management, adding an estimated $14.2K. The largest seller was Sabby Management, exiting entirely with an estimated $107K sold.
- 2 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q3 2021, down from 3 in Q2 2021.
- Funds reported $25K of Lixte Biotechnology Warrants stock for Q3 2021, down 80% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q3 2021 and 1 closed out, a net change of -1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q3 2021 was Warberg Asset Management, an estimated $14.2K added.
- The largest Lixte Biotechnology Warrants seller in Q3 2021 was Sabby Management, an estimated $107K sold.
Based on aggregated 13F filings for Q3 2021.